Posts

Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses – key facts and context

on

Novo Nordisk and Alvotech Face Continued FDA Scrutiny at Plants Tied to Recent FDA Rejections

on

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada

on

Driven by GLP‑1s, Pharma’s Relationship with Consumers Is Starting to Change

on

Novo Nordisk's GLP-1 Pipeline Advances with Oral Innovations Amid Analyst Concerns on Oral Trends

on

Kennedy’s Vaccine Agenda Stalled by Court, Structure’s Obesity Pill Advances, Novo Nordisk Faces FDA Warning

on

Patent Expirations Drive Biopharma Toward a Tougher 2026 with Major Revenue Risks

on

Novo Nordisk Receives FDA Warning Letter for Failing to Report Ozempic Safety Signals Including Deaths

on

Hims Agrees to Limit Compounding, Ending Legal Dispute with Novo Nordisk

on

Novo Nordisk Announces 50% Wegovy List Price Cut to $675 Starting January 2027

on

Friday Five: Novo Nordisk Sues Hims & Hers Over Compounded GLP-1 Drugs Amid FDA Crackdown

on

Friday Five: Novo Nordisk Sues Hims & Hers Over Compounded GLP-1 Drugs Amid FDA Crackdown

on

White House unveils nine new “most-favored-nation” drug pricing deals

on

Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly

on

CMS Unveils Negotiated Prices for Ozempic, Wegovy, and Other Drugs in Second Round of IRA Talks

on

Weight-loss drug stocks drop after Trump pledges major price cuts

on

Novo Nordisk and Bristol Myers Squibb Announce Major Layoffs in New Jersey

on

Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026

on

Execution, Execution, Execution: Novo's New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline

on

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

on